FDA Orphan Drug Designation for EO2463 OncoMimics™ to treat indolent non-Hodgkin lymphoma

“Receiving FDA Orphan Drug Designation is an important regulatory milestone for EO2463 and re-affirms our strong commercial potential. Today, the only option for non-symptomatic low tumor burden “watch-and-wait” iNHL patients is to go without treatment and be observed until the cancer progresses. We believe this places undue stress on patients and their families and is unacceptable; it is gratifying to see the U.S. regulatory agency recognizes that ‘watch-and-wait’ patients deserve a real treatment option like EO2463,” said Pierre Belichard, Chief Executive Officer of Enterome. “Together with the Fast Track designation granted late last year, FDA’s ODD further facilitates and validates our efforts to advance EO2463 toward registrational development in the watch-and-wait population. We are actively engaging with potential partners and investors to find the best path forward to rapidly advance EO2463 development in this indication.”

Share:

More News

Taiho Oncology, Inc. completed a New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA) for zipalertinib in combination with platinum-based chemotherapy for the treatment of patients with previously untreated, locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20

“This collaboration reflects our conviction that atebimetinib has the potential to become an essential backbone therapy in a broad range of combinations across MAPK-driven cancers,” said Ben Zeskind, Immuneering CEO and co-founder. “Atebimetinib’s unique tolerability profile and broad activity make it well suited to combine with a wide range of

“These final updated results provide continued evidence of the potential for γδ T cell therapies to drive activity and improve outcomes for patients,” said William Ho, CEO and co-founder of IN8bio. “The clinical outcomes and observed activity are supported by our correlative analysis, including histopathology, demonstrating the expansion and persistence

“Patients with RAS-mutated mCRC have no first-line therapies specifically approved for their disease, and Fast Track designation reflects the potential of onvansertib to address this serious unmet need,” said Mani Mohindru, PhD, President and Chief Executive Officer of Cardiff Oncology. “Our randomized Phase 2 data give us confidence that onvansertib